Musings on Disease Modification for Parkinson's Disease
Anthony Lang, OC, MD, FRCPC
University of Toronto, Toronto, Canada
Webinar Topic: Musings on Disease Modification for Parkinson's Disease
Webinar Description: This lecture will summarize the reasons for believing that "one drug will not fit all" for disease modification in Parkinson's disease and will highlight the related hypothesis that initial involvement of the substantia nigra (e.g., Braak Stage 3) may trigger an accelerated process driven by factors unique to dopaminergic neurons independent of the status of alpha synuclein aggregation.
- Understand the various types of heterogeneity of Parkinson’s disease
- Recognize the need to consider combinations of disease modifying therapies (i.e. cocktails)
- Consider the possibility that the initial involvement of dopaminergic neurons in PD may trigger an accelerated process that may proceed independent of ongoing spread and toxicity of alpha synuclein
Clinical and basic neuroscientists interested in disease modification in Parkinson’s disease.
This lecture will be made available for on-demand viewing starting on December 2, 2020.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement:
The International Parkinson and Movement Disorder Society designates this activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation.
Participants must complete an evaluation for each session they attend to receive continuing medical education credit. Your chosen session(s) must be attended in their entirety. Partial credit for individual sessions is not available.
Content Validity Statement:
All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.
Disclosure of Financial Relationships:
All individuals in control of content for this webinar are required to disclose all relevant financial relationships with commercial interests as defined by the ACCME. Disclosure information is available here.